Asia Pharma major selected TULA & CM for Oversight and RBM

With strong recommendations from regulatory agencies and in response to increasing complexity, cost of clinical trials, the biopharma companies are actively looking into implementing new monitoring initiatives like Risk-Based Monitoring (RBM), Centralized Monitoring to their clinical studies to ensure quality, compliance, patient safety and oversight. While the trend in implementing these new monitoring approaches has been more in US and EU pharma, companies in Asia are equally adapting and implementing these while highly motivated to make these programs successful.

A TOP 3 Asia HQ pharma company selected TULA & CM for Oversight and RBM with DDi. DDi (Drug Development informatics) a prominent Technology partner to the Life Sciences industry has built its solution competency with a unique blend of functional and domain expertise to serve the technology needs of global clients. Clinical analytics (ClinMetanoia) and vendor oversight risk management (TULA) are provided by DDi with customised dashboard and action oriented triggers and reports.